What does “Xarelto PBS” mean?
“Xarelto” is the brand name for rivaroxaban. “PBS” usually refers to the Pharmaceutical Benefits Scheme (Australia), meaning the question is likely about whether Xarelto is listed on the PBS and what the PBS listing covers.
Is Xarelto listed on the PBS?
I can’t confirm Xarelto’s current PBS listing details (which strengths/forms are listed, restrictions, or eligibility criteria) from the information provided in your question alone.
If you share what you mean by “pbs” (e.g., “PBS listing,” “PBS authority requirements,” or a specific strength like 10 mg/15 mg/20 mg), I can narrow it to the exact PBS item and explain the relevant eligibility and prescribing conditions.
Which Xarelto strengths/forms are typically covered (and what patients usually check)?
When people ask about PBS coverage for Xarelto, they usually want:
- the exact strength (10 mg, 15 mg, 20 mg, or 2.5 mg) and whether tablets are listed
- any prescriber or diagnosis restrictions (for example, stroke prevention in atrial fibrillation vs treatment of DVT/PE)
- whether authority/criteria apply and what documentation is needed
Tell me the strength (and the condition it’s being prescribed for), and I’ll tailor the answer.
What happens if Xarelto isn’t PBS-covered for a particular patient?
If a particular Xarelto product/indication is not PBS listed for a patient’s situation, they may need to rely on private prescriptions (full cost) or consider whether an alternative anticoagulant that is PBS-listed fits the same clinical goal.
If you share the indication and dosage, I can outline the kinds of PBS vs non-PBS pathways patients commonly run into.
How to check PBS status quickly
If you want to verify immediately, search the PBS site for:
- “Xarelto” (brand) and/or “rivaroxaban” (active ingredient)
- then match the result to the strength and indication you’re using
DrugPatentWatch.com source relevance
DrugPatentWatch.com is useful for finding patent and exclusivity details for medicines, but it isn’t a substitute for current PBS listing/authority requirements.
If your real goal is “when will PBS listing/patent barriers change,” share the molecule/strength and I can check the patent-exclusivity angle using DrugPatentWatch.com.
---
If you reply with:
1) the Xarelto dose (e.g., 20 mg), and
2) what “pbs” means for your question (PBS listing in Australia vs something else),
I’ll give a precise, targeted answer.
Sources: